Lyell Immunopharma (NASDAQ:LYEL) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $16.46 and traded as low as $15.50. Lyell Immunopharma shares last traded at $15.64, with a volume of 130,954 shares.

Analyst Ratings Changes

Several brokerages have issued reports on LYEL. HC Wainwright reiterated a “buy” rating on shares of Lyell Immunopharma in a report on Friday, September 11th. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. B. Riley Financial started coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. Finally, Stifel Nicolaus started coverage on shares of Lyell Immunopharma in a research report on Thursday, August 6th. They issued a “buy” rating and a $36.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.86.

Lyell Immunopharma Trading Down 7.2%

The firm has a market cap of $384.59 million, a P/E ratio of -1.25 and a beta of -0.04. The firm has a 50-day simple moving average of $10.99 and a 200-day simple moving average of $16.46.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.01) by $0.15. The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 107.62% and a negative net margin of 1,701,066.75%. Research analysts predict that Lyell Immunopharma, Inc. will post -7.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Arch Venture Partners Ix, Llc acquired 2,321,262 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were bought at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the completion of the transaction, the insider directly owned 3,747,790 shares in the company, valued at $40,363,698.30. This trade represents a 162.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Venture Fund Xiii L.P. Arch bought 2,321,262 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was bought at an average price of $10.77 per share, for a total transaction of $24,999,991.74. Following the purchase, the insider directly owned 3,747,790 shares of the company’s stock, valued at $40,363,698.30. The trade was a 162.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 2,100 shares of company stock valued at $28,757 over the last 90 days. 6.20% of the stock is currently owned by company insiders.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently modified their holdings of the company. Ieq Capital LLC bought a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at about $102,000. Allspring Global Investments Holdings LLC lifted its position in Lyell Immunopharma by 4.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 16,824 shares of the company’s stock valued at $158,000 after acquiring an additional 679 shares during the last quarter. Walleye Capital LLC purchased a new stake in Lyell Immunopharma during the first quarter valued at approximately $445,000. Bank of New York Mellon Corp purchased a new stake in Lyell Immunopharma during the second quarter valued at approximately $347,000. Finally, Bank of America Corp DE boosted its stake in Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after acquiring an additional 25,276 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.